JP2024533427A5 - - Google Patents

Info

Publication number
JP2024533427A5
JP2024533427A5 JP2024515579A JP2024515579A JP2024533427A5 JP 2024533427 A5 JP2024533427 A5 JP 2024533427A5 JP 2024515579 A JP2024515579 A JP 2024515579A JP 2024515579 A JP2024515579 A JP 2024515579A JP 2024533427 A5 JP2024533427 A5 JP 2024533427A5
Authority
JP
Japan
Prior art keywords
fatty acid
group
acid portion
gtfa
conjugate according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533427A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/076198 external-priority patent/WO2023039522A1/en
Publication of JP2024533427A publication Critical patent/JP2024533427A/ja
Publication of JP2024533427A5 publication Critical patent/JP2024533427A5/ja
Pending legal-status Critical Current

Links

JP2024515579A 2021-09-10 2022-09-09 核酸の脂肪酸コンジュゲート Pending JP2024533427A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163242679P 2021-09-10 2021-09-10
US63/242,679 2021-09-10
PCT/US2022/076198 WO2023039522A1 (en) 2021-09-10 2022-09-09 Fatty acid conjugates of nucleic acids

Publications (2)

Publication Number Publication Date
JP2024533427A JP2024533427A (ja) 2024-09-12
JP2024533427A5 true JP2024533427A5 (cg-RX-API-DMAC7.html) 2025-09-16

Family

ID=83508900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515579A Pending JP2024533427A (ja) 2021-09-10 2022-09-09 核酸の脂肪酸コンジュゲート

Country Status (6)

Country Link
US (1) US20240247274A1 (cg-RX-API-DMAC7.html)
EP (1) EP4398939A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024533427A (cg-RX-API-DMAC7.html)
CN (1) CN117980003A (cg-RX-API-DMAC7.html)
CA (1) CA3231700A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023039522A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11060094B2 (en) * 2017-05-19 2021-07-13 Band Therapeutics, Llc Compositions and methods for the treatment of complications and disorders relating to Von Willebrand Factor
JP7699856B2 (ja) * 2021-03-25 2025-06-30 アプタキュア セラピューティクス リミテッド in vivo半減期が延長された核酸分子コンジュゲート
WO2025140190A1 (en) * 2023-12-25 2025-07-03 Microbio (Shanghai) Co., Ltd. Carbon chain-modified nucleic acids and uses thereof for bacterial cell delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CA3057292A1 (en) * 2017-03-22 2018-09-27 The Regents Of The University Of California Modified oligonucleotides and therapeutic uses thereof
WO2021046497A2 (en) * 2019-09-06 2021-03-11 Shen Haifa Orally delivered therapeutical composition and use thereof
CN115397471B (zh) * 2019-11-26 2026-01-23 诺华股份有限公司 包括核酸和半衰期延长基序的化合物
EP4100121A4 (en) * 2020-02-04 2024-04-10 Band Therapeutics, LLC REGULATION OF THE VON WILLEBRAND FACTOR (VWF)
EP4213883A1 (en) * 2020-09-16 2023-07-26 Astrazeneca AB Oligonucleotides conjugated to fatty acids
WO2023009529A2 (en) * 2021-07-28 2023-02-02 Trustees Of Boston University Novel polypeptides and uses thereof

Similar Documents

Publication Publication Date Title
JP5583667B2 (ja) 長時間作用型dnaデンドリマーおよびその方法
JP2022501064A5 (cg-RX-API-DMAC7.html)
US20070066551A1 (en) Aptamer medicinal chemistry
ES2605618T3 (es) ARN de doble cadena, modificado con lípidos con elevado efecto de interferencia por ARN
JP2012509366A5 (cg-RX-API-DMAC7.html)
AR079745A1 (es) Lipidos, composiciones de lipido, metodo de tratamiento y kit
RU2016103695A (ru) СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ
AU2003294437A1 (en) Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
RU2011150787A (ru) КОНЪЮГАТ миРНК И СПОСОБ ЕГО ПОЛУЧЕНИЯ
JP2023537798A5 (cg-RX-API-DMAC7.html)
WO2008034122A2 (en) Hindered ester-based biodegradable linkers for oligonucleotide delivery
JPWO2019074110A1 (ja) 一本鎖核酸分子およびその製造方法
JP2011516094A5 (cg-RX-API-DMAC7.html)
JP2023504186A5 (cg-RX-API-DMAC7.html)
JP2023172954A5 (cg-RX-API-DMAC7.html)
Habus et al. Synthesis, Hybridization Properties, Nuclease Stability, and Cellular Uptake of the Oligonucleotide-Amino-. beta.-cyclodextrins and Adamantane Conjugates
US20240247274A1 (en) Fatty acid conjugates of nucleic acids
JPWO2005078084A1 (ja) 2本鎖オリゴ核酸を担持したポリイオンコンプレックスおよびその製造法とそれを含む医薬組成物
US20130079383A1 (en) Lipid Compounds Targeting VLA-4
IL321125A (en) Analogues of bicyclic abasic nucleic acids and oligomeric compounds prepared therefrom
CA3179016A1 (en) Double-stranded oligonucleotide and composition for treating covid-19 containing same
JP2006067889A (ja) Peoと二本鎖核酸のコンジュゲート
CN101960009A (zh) 阳离子siRNA、合成以及用于RNA干扰的用途
TW202218687A (zh) 骨骼肌遞送載體及其使用方法
JP2024509906A5 (cg-RX-API-DMAC7.html)